A nurse-led intervention addressed completion of preinfusion lab tests, improving patient preparedness for infusion, multidisciplinary coordination, and patient outcomes.
TipRanks on MSN
Bayer backs AskBio gene therapy push in Pompe disease: Early trial update and investor takeaways
Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Study Overview The PROGRESS-GT LOPD trial is an early-stage clinical study ...
NASA opens the International Space Station for scientists and researchers, inviting them to use the benefits of microgravity ...
Market forecasters project the CAR-T cell therapy market will surge from $3.87 billion in 2024 to $13.25 billion by 2030, ...
Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers of Brevard and an assistant professor at the ...
The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...
THE FINAL TWO FLOORS OF THE $215 MILLION EDWIN BARBEY PATIENT CARE PAVILION AT CAPE COD HOSPITAL, NOW READY FOR PATIENTS.
The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ...
New diagnostic chip pulls packets released from tumor cells out of blood, showing whether cancer cells died during ...
In pediatric-onset multiple sclerosis, switching to oral or infusion therapies was linked to fewer relapses than switching between injectable treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback